** Cancer treatment firm Nuvation Bio's NUVB.N shares down 7.1% to $6 and threatening to snap 5-day winning streak on Thurs as it seeks capital raise

** NUVB announces public offering of $200 mln convertible bonds due 2032

** Co intends to use net offering proceeds to fully repay loan agreement, and for general purposes, including working capital, opex and capex

** Also expects to use some proceeds to pay cost of capped call transactions to mitigate potential dilution

** Jefferies, Citigroup and Cantor Fitzgerald joint bookrunners, joined by RBC

** New York City-based NUVB has roughly $2 bln market cap

** With the decline, stock down 33% YTD

** Avg rating of 11 analysts is "buy"; median PT $12, per LSEG data